An official website of the United States government
Home
This neoplasm is not reportable.
Name
Indolent T-lymphoblastic proliferation (IT-LBP)
Reportability
This neoplasm is not reportable
Abstractor Notes
This neoplasm is not reportable, nor has an ICD-O-3 code.
IT-LBP is most frequently identified in mandibular, cervical, supraclavicular, abdominal, retroperitoneal, or oropharyngeal lymph nodes and in upper aerodigestive tract lymphoid tissues.
It is also associated with myasthenia gravis, Castleman disease, hepatocellular carcinoma, follicular dendritic cell sarcoma, nodal T-follicular help cell lymphoma (nTFHL), angioimmunoblastic type lymphoma and acinic cell carcinoma.
iT-LBP is an indolent process that does not require specific treatment. It must be distinguished from T-lymphoblastic leukaemia to avoid unnecessary aggressive therapy.
IT-LBP is most frequently identified in mandibular, cervical, supraclavicular, abdominal, retroperitoneal, or oropharyngeal lymph nodes and in upper aerodigestive tract lymphoid tissues.
It is also associated with myasthenia gravis, Castleman disease, hepatocellular carcinoma, follicular dendritic cell sarcoma, nodal T-follicular help cell lymphoma (nTFHL), angioimmunoblastic type lymphoma and acinic cell carcinoma.
iT-LBP is an indolent process that does not require specific treatment. It must be distinguished from T-lymphoblastic leukaemia to avoid unnecessary aggressive therapy.
Definition
Indolent T-lymphoblastic proliferation (IT-LBP) is an extrathymic non-clonal expansion of T lymphoblasts occurring alone or in association with other disorders, such as Castleman disease. (WHO 5th edition)
Epidemiology and Mortality
Sources
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2024. (WHO classification of tumours series, 5th ed.; vol. 11). https://publications.iarc.who.int/637.
Section: Tumor-like lesions with T-cell predominance
Pages: Part B: 649-650
Section: Tumor-like lesions with T-cell predominance
Pages: Part B: 649-650
